New Delhi News

Pulmonary Embolism Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),|Key Companies – Regeneron Pharmaceutical, Novartis, Pfizer Roche

 Breaking News
  • No posts were found

Pulmonary Embolism Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),|Key Companies – Regeneron Pharmaceutical, Novartis, Pfizer Roche

May 18
02:33 2023
Pulmonary Embolism Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032),|Key Companies - Regeneron Pharmaceutical, Novartis, Pfizer Roche
DelveInsight Business Research LLP
DelveInsight’s “Pulmonary Embolism Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Pulmonary Embolism, historical and forecasted epidemiology as well as the Pulmonary Embolism market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Pulmonary Embolism Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Pulmonary Embolism, historical and forecasted epidemiology as well as the Pulmonary Embolism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pulmonary Embolism Overview

Pulmonary embolism (PE) is a common and potentially deadly form of venous thromboembolic disease. A PE is a blockage within a pulmonary artery in the lungs. The most common cause of such a blockage is a blood clot that forms in a deep vein in the leg and travels to the lungs, where it gets lodged in a smaller lung artery. Almost all blood clots that cause PE are formed in the deep leg veins. Clots also can form in the deep veins of the arms or pelvis.Half the people who have PE have no symptoms. If they do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg.

Pulmonary Embolism Epidemiology Insights

  • According to American Lung Association (ALA) (2020), PE can be life-threatening. PE affects around 1 in 1,000 people in the US every year.

  • According to Clark et al. (2019), PE is a significant health concern, affecting mainly the adult and elderly population. The overall annual incidence of PE was 0.6 per 1,000. The incidence of PE was rare in the pediatric population at a rate of less than 1 out of 100,000 and relatively common after the age of 75 years at a rate of 1 out of 100. It should be noted that the actual incidence of PE was likely significantly higher as autopsy studies have shown that a premortem diagnosis had occurred in only 30%-45% of patients.

  • As per Willich et al. (2018), empirical estimates of PE incidence rates, based on European cohort studies, range from 0.15 per 1000 population per year in Spain, 0.189 in Italy, 0.342 in the UK, to 0.60 in France. The rates vary partially depending on the setting of the study and the age of the study population. In contrast to population cohort studies, an incidence-based epidemiological model estimated that the PE incidence rate is 0.95 per 1000 population per year and the occurrence of PE events is almost a third of a million per year in the EU.

  • As per Long and Koyfman (2016), submassive PE accounts for approximately 20% of all PE, with up to 5% in-hospital mortality rate.

Click here to learn more about th Pulmonary Embolism Market Landscape

The Report Covers the  Pulmonary Embolism Epidemiology Segmented by:

  •  Pulmonary Embolism incident cases 

  •  Pulmonary Embolism gender-specific cases 

  •  Pulmonary Embolism treated cases 

  •  Pulmonary Embolism severity-specific cases 

Pulmonary Embolism Market Outlook 

The Pulmonary Embolism market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Pulmonary Embolism market trends by analyzing the impact of current Pulmonary Embolism therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Pulmonary Embolism market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pulmonary Embolism market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Pulmonary Embolism market in 7MM is expected to witness a major change in the study period 2019-2032.

 Key Companies Working in the Pulmonary Embolism Market

  • Regeneron Pharmaceuticals

  • Novartis

  • Pfizer

  • Roche

  • Chengdu Kanghong Biotech

  • Kodiak Sciences Inc.

  • Opthea Limited

  • Alkahest Inc

  • Graybug Vision

  • REGENXBIO

And many others 

Pulmonary Embolism Therapies Covered and Analyzed in the Report:

  • Aflibercept

  • MP0112 

  •  601

  • SCT510A

  • ALK4290

  • Bevacizumab

  • Ranibizumab

  • KHK4951

  • Conbercept 

  • ACZ885

And many others 

Learn more about the Key Companies and Emerging Therapies in the  Pulmonary Embolism  Market.

Table of Contents 

  1.  Key Insights 

  2.  Pulmonary Embolism  Introduction 

  3.  Executive Summary of  Pulmonary Embolism        

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  Pulmonary Embolism  Emerging Therapies

  7.  Pulmonary Embolism  Market Outlook

  8.  Market Access and Reimbursement of Therapies

  9.  Market Drivers 

  10.  Market Barriers 

  11.  Appendix

  12.  Report Methodology

  13.  DelveInsight Capabilities

  14.  Disclaimer

Learn about the detailed offerings of the report @ Pulmonary Embolism Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services